Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | MMP2 | P08253 | 3/20 | 0.51 |
| ▸ | ANPEP | P15144 | 3/20 | 0.51 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL85062 | 1.00 | PTPN1 (0.52) | PTPN1MMP2ANPEPNR1H2NR1H3 | |
| SCHEMBL719489 | 1.00 | PTPN1 (0.52) | PTPN1MMP2ANPEPNR1H2NR1H3 | |
| SCHEMBL875282 | 0.90 | PTPN1 (0.43) | PTPN1MMP2ANPEPNPC1HDAC8 | |
| SCHEMBL31080852 | 0.90 | PTPN1 (0.43) | PTPN1MMP2ANPEPNPC1HDAC8 | |
| SCHEMBL877760 | 0.90 | PTPN1 (0.43) | PTPN1MMP2ANPEPNPC1HDAC8 | |
| SCHEMBL8404149 | 0.87 | MMP2 (0.57) | PTPN1MMP2ANPEPALDH1A1BRD4 | |
| SCHEMBL8401945 | 0.87 | MMP2 (0.57) | PTPN1MMP2ANPEPALDH1A1BRD4 | |
| SCHEMBL3973783 | 0.87 | MMP2 (0.57) | PTPN1MMP2ANPEPALDH1A1BRD4 | |
| SCHEMBL22543468 | 0.87 | PTPN1 (0.46) | PTPN1MMP2ANPEPNR1H2NR1H3 | |
| SCHEMBL10058225 | 0.87 | PTPN1 (0.46) | PTPN1MMP2ANPEPNR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 591 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115806518-A | Synthesis method of N-Boc-4-oxo-proline methyl ester | 南京安伦化工科技有限公司 | 2023-03-17 | — | — | CN | claimed |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-12472265-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-11-18 | — | — | US | disclosed |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4640684-A1 | KRAS G12D INHIBITORS AND USES THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2025-10-29 | — | — | EP | disclosed |
| CN-223439791-U | Preparation device of N-Boc-4-oxoproline methyl ester | 南京安伦化工科技有限公司 | 2025-10-17 | — | — | CN | disclosed |
| CN-223439791-U | Preparation device of N-Boc-4-oxoproline methyl ester | 南京安伦化工科技有限公司 | 2025-10-17 | — | — | CN | disclosed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-1064298-A2 | INHIBITORS OF CASPASES | Vertex Pharmaceuticals Incorporated (US) | 2001-01-03 | — | — | EP | disclosed |
| WO-1999047545-A2 | INHIBITORS OF CASPASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-09-23 | — | — | WO | disclosed |
| US-5631385-A | Method for the preparation of N-substituted 4-ketoproline derivatives | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1997-05-20 | — | — | US | disclosed |
| EP-0752419-A2 | Process for the preparation of N-substituted 4-ketoproline derivatives | Degussa Aktiengesellschaft (DE) | 1997-01-08 | — | — | EP | disclosed |
| US-5217963-A | Antiischemic, antiepileptic agent | CIBA-GEIGY CORPORATION (US) | 1993-06-08 | — | — | US | disclosed |
| US-5057506-A | Anticonvulsants, antispasmodic and antischemic agents | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0203891-B1 | CERTAIN PHOSPHONIC ACIDS AND DERIVATIVES | CIBA-GEIGY AG (CH) | 1991-05-15 | — | — | EP | disclosed |
| US-4906621-A | Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade | CIBA-GEIGY CORPORATION (US) | 1990-03-06 | — | — | US | disclosed |
| US-4898854-A | NERVOUS SYSTEM DISORDERS | CIBA-GEIGY CORPORATION (US) | 1990-02-06 | — | — | US | disclosed |
| EP-0203891-A2 | Certain phosphonic acids and derivatives | CIBA-GEIGY AG (CH) | 1986-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD4, CD2, B2M | PTPN1 2381/4885MMP2 1743/4885ANPEP 112/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | PTPN1 2316/4885MMP2 2761/4885ANPEP 3126/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | PTPN1 2337/4885MMP2 1841/4885ANPEP 1497/4885 |
| US-20250346585-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C5, C1S, C9 | PTPN1 3684/4885MMP2 3537/4885ANPEP 1871/4885 |
| US-12472265-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | PTPN1 3907/4885MMP2 1828/4885ANPEP 248/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | PTPN1 1785/4885MMP2 2213/4885ANPEP 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.